Intended Use

The Dreem 3S is intended for prescription use to measure, record, display, transmit and analyze the electrical activity of the brain to assess sleep and awake in the home or healthcare environment, with output of hypnograms and sleep metrics for adults aged 22 to 65 years.

Technology

The device features a wearable headband with 6 dry EEG electrodes and a 3D accelerometer to gather physiological signals. It transmits raw data to servers where an artificial neural network processes frequency spectra through recurrent and attention layers to classify sleep stages automatically every 30 seconds according to AASM standards. It includes a bone-conduction speaker for notifications and allows export of raw EDF data files.

Performance

Clinical performance was validated in a study comparing Dreem 3S automated sleep staging to expert-scored polysomnography (PSG) in 38 adults with disturbed sleep, showing high positive agreement for most sleep stages (e.g. 88.5% for wake, 83.4% for N2, 91.57% for REM). EEG data quality was sufficient for manual review with 96.6% epochs deemed scorable. Usability testing demonstrated patient tolerability.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    11/23/2022

    8 months
  • 2

    FDA Approval

    8/18/2023

Other devices from Beacon Biosignals, Inc.

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.